PLK1 and cancer: On the other hand, when the core PLK1 pathway is specifically inhibited (e.g., by cryptotanshinone), cancer cells might activate other compensatory survival pathways (such as the Ras or cAMP pathways indicated by the enrichment analysis) to sustain their malignant phenotype, representing a potential mechanism for drug resistance.